![Rank: 8](static/image/common/star_level3.gif) ![Rank: 8](static/image/common/star_level3.gif)
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 风雨不动 于 2012-4-14 15:33 编辑
http://www.marketwire.com/mw/rel_us_print.jsp?id=1400000
SOURCE: Dynavax Technologies
Feb 22, 2011 16:30 ET
Dynavax Reports Additional Positive Phase 1B Immunogenicity Data for Hepatitis B Therapy Candidate
BERKELEY, CA--(Marketwire - February 22, 2011) - Dynavax Technologies Corporation (NASDAQ: DVAX)reported in a poster session Saturday, February 19 at the 21stConference of the Asian Pacific Association for the Study of the Liver(APASL 2011) in Bangkok, Thailand new Phase 1b immunogenicity data forDV-601, its proprietary hepatitis B therapeutic vaccine. The studyevaluated three doses of the candidate therapeutic vaccine escalationin 14 patients with chronic hepatitis B infection, including sixpatients that were HBeAg negative and eight patients who were HBeAgpositive, and found:
- The therapeutic regimen was safe and generally well tolerated at all dose levels;
- Most common systemic reactions were fatigue and malaise. No SAEs were recorded;
- DV601was found to elicit immune responses at all dose levels, andanti-HBe antibodies were elicited in two of eight (2/8) patients;
- Anti-HBs antibodies were elicited in four of 14 (4/14) patients;
- Amongst the eight HBeAg positive patients, two had HBeAg clearance, and one of those individuals also had HBsAg clearance;
- Three patients are still in the follow-up observation period.
Accordingto Tyler Martin, M.D., President and Chief Medical Officer, "This trialwas primarily designed to assess the safety of our vaccine. Thepositive immunogenicity results, in particular, the two HBeAgseroconversions, including one HBsAg serocoversion, provide a strongrationale for an expanded evaluation of our approach in collaborationwith a potential partner."
Dynavax in December 2010reported that all doses were generally safe and well tolerated and thatindividual immunologic and virologic responses had been observed acrosscohorts at all dose levels.
Dynavax's treatmentapproach combines both the surface and core hepatitis B virus (HBV)antigens with ISCOMATRIX® adjuvant originally entered into developmentby Rhein Biotech prior to its acquisition by Dynavax in 2006. Thecandidate vaccine, DV-601, is designed to induce an immune responseagainst HBV-infected cells and if proven to be safe and effective, mayoffer an alternative therapeutic option for patients chronicallyinfected with HBV.
About Dynavax
DynavaxTechnologies Corporation, a clinical-stage biopharmaceutical company,discovers and develops novel products to prevent and treat infectiousdiseases. The Company's lead product candidate is HEPLISAV™, a Phase 3investigational adult hepatitis B vaccine designed to enhanceprotection more rapidly with fewer doses than current licensedvaccines. For more information, visit www.dynavax.com.
ISCOMATRIX® is a registered trademark of ISCOTEC AB, a CSL Limited Company
(6.合.彩).足球.篮球...各类投注开户下注
第一投注.现金网:招代理年薪10万以上:6668.cc |
|